Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

Study acronym: SIBO in PDAC
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 6 months later Apr 14, 2026 → Oct 14, 2028
See other at-risk trials from Cedars-Sinai Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Apr 14, 2026 to Oct 14, 2028
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.
Trial Details
NCT Number NCT06988150
Lead Sponsor Cedars-Sinai Medical Center
Conditions
(from sponsor)		 Pancreatic Adenocarcinoma, Weight Loss
Related terms Weight Loss
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov